Murohashi Ikuo, Kashimura Takuya, Tominaga Kazunori, Wakao Daisuke, Takahashi Takashi, Akiba Miki, Kishimoto Kuniya, Yoshida Katsuhiko, Yagasaki Fumiharu, Itoh Yoshihiro, Sakata Tohru, Kawai Nobutaka, Itoh Katsurou, Suzuki Toshiya, Matsuda Akira, Hirashima Kunitake, Bessho Masami
First Department of Internal Medicine, Saitama Medical School, Morohongo 38, Moroyama-machi, Iruma-gun, Saitama 350-0451, Japan.
Leuk Res. 2002 Mar;26(3):229-34. doi: 10.1016/s0145-2126(01)00114-x.
Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regimen had a 41% (9/22) overall response rate compared with 48% (13/27) for the MEP plus carboplatin (C-MEP) regimen (Chi-squared test, P=0.602). Among 38 CHOP-resistant patients, however, the overall response rate to C-MEP [42% (10/24)] was significantly superior compared with MEP [7% (1/14)] (P=0.023), and the overall survival to C-MEP was superior compared with MEP (P=0.088). Taken together, our results, although non-randomized, suggest that a combination of MEP with carboplatin is better than MEP alone in CHOP-resistant diffuse large B-cell lymphomas.
Zotero 插件